My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: Usually no — compounded GLP‑1s are not the best first option. Try appeals and manufacturer/insurance solutions or an alternative FDA‑approved product first. Compounded versions carry safety, quality, legal and coverage risks and should be a last resort handled only by an accredited sterile compounding pharmacy under close clinical supervision.

Why not compounded GLP‑1s first

• Not FDA‑approved: purity, potency and sterility aren’t guaranteed the way brand drugs are.
• Safety risk: injectables must be made in sterile conditions (risk of contamination, dosing errors).
• Insurance usually won’t cover them.
• Less clinical evidence: compounded combos/doses haven’t gone through trials for efficacy/safety.
• Legal/regulatory gray area: can be restricted by state boards and insurers.

What to try first (recommended)

1. Appeal the denial / prior authorization: ask your prescriber to submit a PA with documentation of BMI, medical history and prior weight‑loss attempts; request a peer‑to‑peer review with the insurer.
2. Manufacturer help: contact Novo Nordisk about Wegovy support — they offer savings cards and patient assistance programs for eligible patients (these can sharply reduce or eliminate out‑of‑pocket cost for commercially insured or low‑income uninsured patients; note copay cards aren’t allowed for Medicare).
3. Alternatives that might be covered: ask your clinician about other FDA‑approved options that some plans cover differently — Zepbound (tirzepatide, Eli Lilly) and Saxenda (liraglutide, Novo Nordisk) are approved for weight management; Ozempic/Rybelsus or Mounjaro (diabetes indications) are sometimes covered and used off‑label for weight loss (discuss safety/monitoring). Eli Lilly and Novo Nordisk both have patient support programs you can ask about.
4. Short‑term clinic strategies: samples from your prescriber, in‑clinic starter supplies, or enrollment in a supervised weight‑management program while you resolve coverage.

If you consider a compounded GLP‑1

• Only as a last resort and only if you and your prescriber accept the risks.
• Use a reputable compounding pharmacy: confirm they follow USP sterile compounding standards (USP <797>), have third‑party compounding accreditation (for example PCAB or equivalent), and can provide certificates of analysis/lot testing for sterility and potency.
• Ask the pharmacy who supplied the active pharmaceutical ingredient (API) and for documentation of testing.
• Keep close medical follow‑up and lab monitoring for side effects (blood glucose, kidney function, etc.).
• Expect out‑of‑pocket payment; check legal/insurance implications (Medicare usually won’t accept manufacturer coupons and may have additional rules).

Specific names/services to contact

• Wegovy (semaglutide) — Novo Nordisk: ask about the Wegovy savings card and Novo Nordisk patient assistance.
• Zepbound (tirzepatide) — Eli Lilly: ask Lilly’s patient support programs about access/cost help.
• Saxenda (liraglutide) — Novo Nordisk (older GLP‑1 weight option).
• GoodRx or single‑care price comparison sites can show cash prices if you’re paying out of pocket.
• Ask for compounding pharmacies that are PCAB‑accredited and adhere to USP sterile compounding standards if you ever go that route.

If you want, tell me: are you on Medicare or private insurance, and did the insurer give a reason for denial? I can suggest next steps tailored to your situation and, if you’re considering a compounded product, questions to ask a compounding pharmacy and a brief checklist to evaluate them.